Ionis Pharmaceuticals, Inc. cash flow to debt ratio of -10.27% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Ionis Pharmaceuticals, Inc.'s free cash flow has increased -41.41% from $-546.23M last year to $-320.03M, signaling increasing performance

Ionis Pharmaceuticals, Inc.'s debt to equity ratio is 5.50, which means that the company's assets are unhealthy financed, signaling financial risk.

Ionis Pharmaceuticals, Inc.'s debt has increased relative to shareholder equity from 2.41 last year to 5.50 today, signaling weakened financials

Ionis Pharmaceuticals, Inc. has a net cash position, so leverage is healthy.

Ionis Pharmaceuticals, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Ionis Pharmaceuticals, Inc.'s profit margin has decreased (0.42%) in the last year from -64.37% to -64.64%, signaling decreasing performance

Ionis Pharmaceuticals, Inc.'s short-term assets of $2.99B exceed its short-term liabilities of $781.57M

Ionis Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Ionis Pharmaceuticals, Inc.'s return on equity of -110.84%, is lower than 15.00%, indicating bad performance

Ionis Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Ionis Pharmaceuticals, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Ionis Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Ionis Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

Ionis Pharmaceuticals, Inc.'s yearly earnings has increased -16.06% since last year from $-453.90M to $-381.00M, signaling increasing performance

Ionis Pharmaceuticals, Inc.'s yearly revenue has increased 33.87% since last year from $705.14M to $944.00M, signaling increasing performance

ROIC -20.37% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Ionis Pharmaceuticals, Inc.'s 3-year revenue CAGR of 17.14% is positive, indicating growing revenue over the past 3 years

Ionis Pharmaceuticals, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Ionis Pharmaceuticals, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Ionis Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Ionis Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Ionis Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Ionis Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Ionis Pharmaceuticals, Inc. is overvalued relative to its fair value price of -39.97 based on Earnings Fair Value model

Ionis Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Ionis Pharmaceuticals, Inc. has a price-to-book ratio of 21.45x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Ionis Pharmaceuticals, Inc. has a price-to-sales ratio of 10.78x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue